Test of anti-cancer medicine before lung surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial tests cadonilimab given before surgery for resectable stage II to IIIA squamous cell lung cancer. It aims to shrink or control the cancer before an operation and see how well that approach works and is tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell lung cancer that can be removed by surgery (stage II to IIIA) and you have not had cancer treatment before.
- Your overall health/function is good to okay, such as ECOG performance status of 0 or 2.
- Your doctors can measure at least one visible cancer spot on scans that meets study size rules.
- Your organs (like blood counts, kidneys, and liver) are working well enough for treatment.
- You do not have a different lung cancer type (no mixed adenocarcinoma or small cell lung cancer).
- You do not have certain recent cancers, active autoimmune disease, or recent immune-suppressing medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at giving immunotherapy before surgery for certain early-stage lung cancers to help shrink the tumor and improve outcomes. It is mainly for people whose lung cancer can be removed by surgery and who don’t have specific gene changes like EGFR or ALK.
This trial tests whether giving two immunotherapy drugs directly into the tumor before surgery can shrink non-small cell lung cancer and improve outcomes. It is for people with early-stage (IIIA) lung cancer who are candidates for surgery.
This trial tests a new immunotherapy drug (cadonilimab) combined with standard chemotherapy, given before and after surgery for lung cancer that has very low PD-L1. The goal is to see if this combination helps shrink the tumor and prevents it from coming back.
This Phase II trial tests whether a penpulimab-based combination treatment, given before and after surgery, can improve outcomes for people with operable, locally advanced non-small cell lung cancer. It mainly aims to treat the cancer earlier (before surgery) and help prevent it from coming back (after surgery).
This trial tests a new drug called cadonilimab for people with advanced non-squamous non-small cell lung cancer that has gotten worse after treatment with immunotherapy and chemotherapy. The goal is to see if it helps control the cancer.
This trial tests a new drug called cadonilimab combined with chemotherapy for people with advanced lung cancer who have already tried and failed immunotherapy. It aims to see if this combination can help when standard immunotherapy no longer works.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.